Back to Treatments

Treatment

Natalizumab

1
Conditions
126
Trials
2,000
Participants
35%
Average Safety

Condition Evidence

Multiple sclerosis

126 trials · 2,000 participants

92% effectiveness · 35% safety
Natalizumab | DFDA